Published in Health Risk Factor Week, August 25th, 2009
"SK is cheaper and more widely available, but it appears less effective because it lacks TPA's fibrin-targeted properties that focus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.